Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2013-08-26 | Barry D. Quart, Pharm.D., Chief Executive Officer, Director, includes 37,100 shares of common stock and 1,483,677 shares underlying stock options exercisable within 60 days of July 31, 2013. |
| 2014-04-24 | Barry D. Quart, Pharm.D. has served as a member of our Board since June 2012. Dr. Quart was appointed Chief Executive Officer in May 2013. Compensation that Dr. Quart received as director prior to being Named Executive Officer is fully reflected in the Summary Compensation Table. Summary Compensation Table shows total compensation for Dr. Quart in 2013 as $8,256,214. |
| 2015-04-28 | Barry D. Quart, Pharm.D. has served as a member of our Board of Directors since June 2012. Dr. Quart was appointed Chief Executive Officer of the Company in May 2013. ... Dr. Quart and Mr. Rosen are not deemed to be independent under NASDAQ rules by virtue of their current employment with the Company. |
| 2016-04-29 | Barry D. Quart, Pharm.D. has served as a director of Heron since June 2012. Dr. Quart was appointed Chief Executive Officer of the Company in May 2013. ... Dr. Quart and Mr. Rosen are not deemed to be independent under NASDAQ rules by virtue of their current employment with the Company. ... The following tables and descriptive materials set forth information concerning compensation earned for services rendered to us by our Named Executive Officers during fiscal 2015, 2014 and 2013. ... Barry D. Quart, Pharm.D. 2015 ... Total 6,475,887 ... Compensation Discussion and Analysis ... The grant-date fair value of the equity awards granted in 2015, as reflected under Option Awards, represents an annual grant for 2015 services awarded in December 2015. |
| 2017-04-26 | Barry D. Quart, Pharm.D. has served as a director of Heron since June 2012. Dr. Quart was appointed Chief Executive Officer of the Company in May 2013. ... Dr. Quart's qualifications to serve on our Board include his experience in senior management and as a director with other biotechnology and pharmaceutical companies and his prior drug development experience. ... The following tables and descriptive materials set forth information concerning compensation earned for services rendered to us by our Named Executive Officers during fiscal 2016: ... Barry D. Quart, Pharm.D. 2016 Salary $579,143 Option Awards $2,976,744 Non-Equity Incentive Plan Compensation $208,492 All Other Compensation $7,950 Total $3,772,329. |
| 2018-04-30 | Barry D. Quart, Pharm.D. has served as a director of Heron since 2012. Dr. Quart was appointed Chief Executive Officer of the Company in 2013. ... The Summary Compensation Table shows total compensation for 2017 as $4,243,100. |
Data sourced from SEC filings. Last updated: 2025-12-06